Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Metals One

    MCap

    —

    Last close

    GBP0.01

    ▲ 0.18 (19.44%)

    Elevra Lithium

    MCap

    AUD751m

    Last close

    AUD4.45

    ▲ 0.56 (14.40%)

    ADS-TEC Energy

    MCap

    USD569m

    Last close

    USD11.42

    ▲ 1.06 (10.23%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Executive Interview – NeuroVive Pharmaceutical (Part 3)

Executive Interview – NeuroVive Pharmaceutical (Part 3)

NeuroVive is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT) and one project in clinical Phase I (KL1333) for genetic mitochondrial diseases. Here, CEO Erik Kinnman speaks about the progress KL1333 has made over the past month – receiving orphan drug designation in Europe and the status of the first clinical trial.

< Previous
Next >

You may also be interested in these:

Healthcare

Herantis Pharma – executive interview

Investment Companies

Finsbury Growth & Income Trust – equity proposition